Skip to main content

Advertisement

Table 1 Baseline Characteristics

From: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

  Number Percent
Sex (Male) 40 67
Ethnic Origin (Caucasian) 59 98
Age (Years) 61 (median)  
Stage
   M1A 10 17
   M1B 8 13
   M1C 42 70
Common Lesion Sites
   Lung 28 47
   Liver 28 47
   Lymph Nodes 23 38
   Subcutaneous 16 27
   Bone 13 22
   Spleen 3 5
   Adrenal Glands 3 5
Chemo- Naïve 11 18
Prior Chemo Exposure 49 82
Previous Systemic Treatments
   0 11 18
   1 18 30
   2 17 28
   3 9 15
   4 4 7
   5 1 2
Previous Adjuvant Therapy
   Dacarbazine/IL-2 16 27
   IFN 5 8
Previous Active Therapy
   Biochemotherapy 26 43
   High Dose IL-2 8 13
   Anti-CTLA4 7 12
   Temozolomide 7 12
   Vaccine 7 12